Filing Flows › Companies › BridgeBio Pharma › Timeline
BridgeBio Pharma stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+18.4% to $74.29
BridgeBio Pharma (BBIO) stock rose 18% over the last 252 sessions, to $74.29. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 10 Form 144 notices of planned sales, and the company filed 5 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 29, 2026 | Earnings | Earnings: beat the EPS estimate by 24.6% | −0.1% (+0.3% vs SPY) | +9.5% (+10.2% vs SPY) | — |
| Aug 19, 2026 | Form 144 | Form 144: Kumar Haldea Family Irrevocable TRU/T/A DTD 05/18/2019 plans to sell $2.5M | +1.2% (+1.0% vs SPY) | −3.2% (−3.0% vs SPY) | −20.9% (−20.3% vs SPY) |
| Aug 18, 2026 | Form 144 | Form 144: Neil Kumar plans to sell $2.8M | +3.8% (+4.5% vs SPY) | +1.5% (+2.6% vs SPY) | −15.7% (−13.2% vs SPY) |
| Aug 17, 2026 | 8-K | Material definitive agreement | 0.0% (+0.5% vs SPY) | +2.0% (+3.4% vs SPY) | −15.5% (−13.0% vs SPY) |
| Aug 17, 2026 | Form 144 | Form 144: Randal Scott plans to sell $1.7M | 0.0% (+0.5% vs SPY) | +2.0% (+3.4% vs SPY) | −15.5% (−13.0% vs SPY) |
| Aug 10, 2026 | Earnings | Earnings: missed the EPS estimate by -33.9% | +0.2% (+0.3% vs SPY) | −5.6% (−6.0% vs SPY) | −12.2% (−11.3% vs SPY) |
| Jul 9, 2026 | Form 144 | Form 144: Andrea Ellis plans to sell $1.4M | +14.1% (+13.2% vs SPY) | +5.4% (+4.1% vs SPY) | +5.6% (+2.5% vs SPY) |
| Jul 9, 2026 | Form 144 | Form 144: Jennifer Cook plans to sell $13.2M | +14.1% (+13.2% vs SPY) | +5.4% (+4.1% vs SPY) | +5.6% (+2.5% vs SPY) |
| Jul 2, 2026 | 8-K | Material definitive agreement | +0.7% (−0.2% vs SPY) | +10.7% (+9.3% vs SPY) | +3.5% (+1.8% vs SPY) |
| Jun 26, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.8% (+1.5% vs SPY) | +10.2% (+8.8% vs SPY) | +18.8% (+18.2% vs SPY) |
| Jun 24, 2026 | Form 144 | Form 144: Jennifer Cook plans to sell $2.6M | +1.1% (+1.1% vs SPY) | +8.2% (+6.4% vs SPY) | +18.9% (+18.3% vs SPY) |
| Jun 24, 2026 | Form 144 | Form 144: Randal Scott plans to sell $151K | +1.1% (+1.1% vs SPY) | +8.2% (+6.4% vs SPY) | +18.9% (+18.3% vs SPY) |
| Jun 23, 2026 | Form 144 | Form 144: Hannah A Valantine plans to sell $151K | −0.4% (+1.0% vs SPY) | +4.4% (+4.9% vs SPY) | +18.2% (+17.8% vs SPY) |
| Jun 23, 2026 | Form 144 | Form 144: Jennifer Cook plans to sell $151K | −0.4% (+1.0% vs SPY) | +4.4% (+4.9% vs SPY) | +18.2% (+17.8% vs SPY) |
| Jun 22, 2026 | Form 144 | Form 144: Hannah A Valantine plans to sell $191K | +3.9% (+4.2% vs SPY) | +5.8% (+8.2% vs SPY) | +21.9% (+21.7% vs SPY) |
| May 8, 2026 | 8-K | Material definitive agreement | −0.1% (−0.9% vs SPY) | +3.2% (+1.0% vs SPY) | −0.1% (−1.2% vs SPY) |
| May 7, 2026 | Earnings | Earnings: missed the EPS estimate by -36.2% | −0.9% (−0.6% vs SPY) | +0.8% (−0.4% vs SPY) | −0.7% (−1.2% vs SPY) |
| Feb 24, 2026 | Earnings | Earnings: missed the EPS estimate by -50.6% | +0.6% (−0.1% vs SPY) | −3.6% (−4.2% vs SPY) | +0.9% (+5.0% vs SPY) |
| Jan 21, 2026 | 8-K | Material definitive agreement | +2.2% (+1.7% vs SPY) | −0.8% (−2.3% vs SPY) | −13.7% (−14.3% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
| 1.02 Termination of a material agreement | 2,368 | 0.0% | 51% | +1.1% | ±1.5% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → BridgeBio Pharma: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.